Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment

BACKGROUND: Personalized mRNA vaccines are promising new therapeutic options for patients with cancer. Because mRNA vaccines are not yet approved for first-line therapy, the vaccines are presently applied to individuals that received prior therapies that can have immunocompromising effects. There is...

Descripción completa

Detalles Bibliográficos
Autores principales: Donhauser, Lara Victoria, Veloso de Oliveira, Julia, Schick, Cordula, Manlik, Wenzel, Styblova, Sabrina, Lutzenberger, Sarah, Aigner, Michael, Philipp, Patrick, Robert, Sebastian, Gandorfer, Beate, Hempel, Dirk, Hempel, Louisa, Zehn, Dietmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510941/
https://www.ncbi.nlm.nih.gov/pubmed/37730271
http://dx.doi.org/10.1136/jitc-2023-007387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510941/
https://www.ncbi.nlm.nih.gov/pubmed/37730271
http://dx.doi.org/10.1136/jitc-2023-007387

Ejemplares similares